Investors with a lot of money to spend have taken a bullish stance on Eli Lilly LLY.
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with LLY, it often means somebody knows something is about to happen.
So how do we know what these investors just did?
Today, Benzinga's options scanner spotted 46 uncommon options trades for Eli Lilly.
This isn't normal.
The overall sentiment of these big-money traders is split between 50% bullish and 39%, bearish.
Out of all of the special options we uncovered, 8 are puts, for a total amount of $378,149, and 38 are calls, for a total amount of $5,040,761.
What's The Price Target?
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $750.0 and $1080.0 for Eli Lilly, spanning the last three months.
Volume & Open Interest Development
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Eli Lilly's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Eli Lilly's whale trades within a strike price range from $750.0 to $1080.0 in the last 30 days.
Eli Lilly Option Volume And Open Interest Over Last 30 Days
Noteworthy Options Activity:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| LLY | CALL | TRADE | NEUTRAL | 12/19/25 | $70.15 | $67.5 | $69.0 | $1000.00 | $2.7M | 300 | 1 |
| LLY | CALL | TRADE | BULLISH | 12/19/25 | $70.0 | $65.9 | $69.0 | $1000.00 | $690.0K | 300 | 401 |
| LLY | CALL | TRADE | BULLISH | 12/19/25 | $135.8 | $134.3 | $135.8 | $840.00 | $162.9K | 142 | 0 |
| LLY | PUT | SWEEP | BEARISH | 02/28/25 | $12.0 | $11.75 | $12.0 | $870.00 | $97.2K | 98 | 183 |
| LLY | CALL | TRADE | BULLISH | 04/17/25 | $37.7 | $36.85 | $37.7 | $880.00 | $79.1K | 208 | 28 |
About Eli Lilly
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Having examined the options trading patterns of Eli Lilly, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
Present Market Standing of Eli Lilly
- With a volume of 1,600,917, the price of LLY is up 0.69% at $873.03.
- RSI indicators hint that the underlying stock may be overbought.
- Next earnings are expected to be released in 70 days.
Professional Analyst Ratings for Eli Lilly
A total of 3 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $1066.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. Click here for access. * Maintaining their stance, an analyst from Wells Fargo continues to hold a Overweight rating for Eli Lilly, targeting a price of $970. * Maintaining their stance, an analyst from Truist Securities continues to hold a Buy rating for Eli Lilly, targeting a price of $1038. * Consistent in their evaluation, an analyst from Citigroup keeps a Buy rating on Eli Lilly with a target price of $1190.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Eli Lilly options trades with real-time alerts from Benzinga Pro.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
